论文部分内容阅读
观察了72例接受不同方法治疗的晚期消化道恶性肿瘤患者愈后及γ显像情况,患者随机分为3组,第一组21例单独应用131I标记的抗结肠癌单克隆抗体CL3(简称131I-CL3)局部多点注射治疗;第二组33例接受LAK细胞/IL-2静脉注射治疗;第三组18例接受LAK细胞/IL-2联合131I-CL3肿瘤局部多点注射治疗。发现:(1)LAK细胞/IL-2和131I-CL3联合应用组,肿瘤局部核素标记抗体浓聚大于131I-CL3组。(2)联合应用LAK细胞/IL-2及131I-CL3治疗组的有效率(CR+PR,50%)明显高于131I-CL3治疗组(238%)及LAK细胞/IL-2治疗组(121%)。说明LAK细胞/IL-2联合应用后可增强放免显像及放免治疗的效果。
72 patients with advanced gastrointestinal cancer treated with different methods were observed and gamma imaging was performed. The patients were randomly divided into 3 groups. The first group of 21 patients were treated with 131I-labeled anti-colonic cancer monoclonal antibody CL3 (abbreviated as 131I). -CL3) local multi-point injection therapy; 33 patients in the second group received LAK cell/IL-2 intravenous injection; 18 patients in the third group received LAK cell/IL-2 combined with 131I-CL3 tumor local multipoint injection. The findings were as follows: (1) LAK cells/IL-2 and 131I-CL3 combined application group, tumor local nuclide-labeled antibody concentration was greater than 131I-CL3 group. (2) The combined use of LAK cells/IL-2 and 131I-CL3 treatment group was significantly more effective (CR+PR, 50%) than 131I-CL3 treatment group (238%) and LAK cells/IL-2 treatment group ( 121%). This shows that the combination of LAK cells/IL-2 can enhance the efficacy of radioimmunoassay and radioimmunotherapy.